Advances in Cancer Biology and Experimental Anticancer Therapies (3rd Edition)
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: 30 November 2026 | Viewed by 1008
Editors
Interests: immunotoxin; immunoconjugate; immunotargeting; plant toxins; ribosome-inactivating proteins
Special Issues, Collections and Topics in MDPI journals
Interests: cancer cell biology; biomarkers; micro-RNAs; multidrug resistance; experimental anticancer therapies
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Currently, chemotherapy, surgery, and radiotherapy are the most commonly available cancer treatments. However, despite their demonstrated anti-tumour efficacy, the use of radiotherapy and chemotherapeutic agents has shown many limitations, such as the lack of selectivity for tumour cells, the development of drug resistance, and the appearance of secondary malignancies. As a result, the study and development of alternative targeted therapies, such as immunotherapy and nanotherapy, have been extensively researched in order to find therapies with greater specificity for transformed cells and a lower non-specific toxicity. Therefore, it is essential that we intensify our studies on the molecular mechanisms of carcinogenesis and develop new tactics to diagnose and fight tumours.
In this Special Issue, we aim to provide an update on the most promising anticancer therapeutic strategies and current studies on the molecular factors that influence cancer biology.
Dr. Letizia Polito
Dr. Ewa Gajda
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer biology
- experimental anticancer therapies
- immunotherapy
- immunotoxins
- signalling pathways
- targeted therapies
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
